1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE
| 中文名称 | 1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE |
|---|---|
| 中文同义词 | 化合物J-113863;1-(1-环辛烯-1-基甲基)-4-[[(2,7-二氯-9H-氧杂蒽-9-基)羰基]氨基]-1-乙基哌啶鎓碘化物 |
| 英文名称 | 1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE |
| 英文同义词 | 1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE;J 113863;CCR,Inhibitor,inhibit,rheumatoid,J-113863,CCR1,CCR3,CC chemokine receptor,Chemotaxis,collagen,arthritis,J 113863,J113863,CD18,anti-inflammatory |
| CAS号 | 353791-85-2 |
| 分子式 | C30H37Cl2IN2O2 |
| 分子量 | 655.44 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 353791-85-2.mol |
| 结构式 | ![1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE 结构式](CAS/GIF/353791-85-2.gif) |
1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE 性质
| 储存条件 | Store at +4°C |
|---|---|
| 溶解度 | 在 DMSO 中溶解度为 100 mM，在乙醇中溶解度为 50 mM |
| 形态 | 粉末 |
| 颜色 | 浅黄至黄色 |
1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE 用途与合成方法
|
CCR1 0.9 nM (IC 50 , Human CCR1) |
CCR1 5.8 nM (IC 50 , Mouse CCR1) |
CCR3 0.58 nM (IC 50 , Human CCR3) |
CCR3 460 nM (IC 50 , Mouse CCR3) |
Modified Vaccinia virus Ankara (MVA) but not MVA and vaccinia virus (VACV) infected MH-S cells increase the expression of the CXCR2 acting chemokine CXCL2. MH-S cells constitutively produce CCL2 and CCR1 acting chemokines CCL3, CCL5 and CCL9. Consequently, supernatants of mock treated and virus infected MH-S cells induce chemotaxis of murine promyelocyte MPRO cells and human monocytic THP-1 cells at the same level. However, supernatants of MVA infected MH-S cells significantly increase chemotaxis of the CCR2 deficient human monocytic cell line U-937. Chemotaxis of all above cell types is inhibited by J-113863.
J-113863 (3-10 mg/kg; intraperitoneal injection; once daily; for 11 days; DBA-1 male mice) treatment improves paw inflammation and joint damage, and dramatically decreases cell infiltration into joints in arthritic mice.
| Animal Model: | DBA-1 male mice (10-12 weeks) induced with Collagen |
| Dosage: | 3 mg/kg, 10 mg/kg |
| Administration: | Intraperitoneal injection; once daily; for 11 days |
| Result: | Improved paw inflammation and joint damage, and dramatically decreased cell infiltration into joints. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-103360 | J-113863 | 1 mg | 727元 | |
| 2024/04/30 | HY-103360 | 1,4-CIS-1-(1-CYCLOOCTEN-1-YLMETHYL)-4-[[(2,7-DICHLORO-9H-XANTHEN-9-YL)CARBONYL]AMINO]-1-ETHYLPIPERIDINIUM IODIDE J-113863 | 353791-85-2 | 5mg | 1600元 |